Clinical trial · Observational
Ovarian Cancer Hemoscope Trial
NCT02811224CI-TRIAL-00084775active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, gold standard observational trial designed to enroll consecutive, consenting ovarian cancer patients for the purpose of determining sensitivity of an assay that detects circulating tumor DNA. This observational pilot trial will also be used to examine the genetic variants/mutations present in the tumor tissue DNA.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Neoplasms | Ovarian Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Ovarian Cancer
- label
- Benign Neoplasm
Primary outcomes (1)
- measure
- Sensitivity of an assay that detects circulating tumor DNA
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Case Group * Patients with ovarian cancer undergoing surgery (all stages) * Over 18 years old Control Group * Patients with a benign gynecological condition undergoing surgery * Over 18 years old Exclusion Criteria: * Previous cancer diagnosis (all) * Radiation therapy before surgical treatment * Bone marrow transplant * Chemotherapy before surgical treatment * Invasive procedure resulting in damage to tissue (e.g., surgery, biopsy, thermal ablation) in the 7 days prior to baseline (pre-surgical) blood collection
References
Publications (0)
Data not yet available
No reference posted for this study.